Blossom x Report on Psychedelics Briefings
In the Research Briefing of January 10th: 1) Psilocybin can be administered safely for up to six people simultaneously 2) An Open Science approach toward MDMA synthesis 3) Nitrous Oxide could be the next antidepressant
In the Research Briefing of December 20th: 1) New double-blind study doesn’t find benefits of microdosing 2) The negative post-acute effects of MDMA appear to be absent in the clinical setting
In the Research Briefing of December 6th: 1) The methodological challenges faced in psychedelic clinical trials (and how to fix them) 2) Mystical experiences in recreational use associated with improvements in wellbeing 3) A novel 5-MeO-DMT formulation proves to be safe in Phase I trial
In the Research Briefing of November 22nd: 1) Those who microdose report lower anxiety & depression 2) Psilocybin therapy increases cognitive and neural flexibility 3) How can psilocybin help decrease craving in alcoholism
In the Research Briefing of November 8th: 1) To patent or not to patent psychedelics 2) Getting psychedelics to a community clinic near you 3) The influence of cannabis on psychedelic experiences
In the Research Briefing of October 25th: 1) A summary of what we know about 5-MeO-DMT 2) Investigating ketamine’s chemical structure for safety and efficacy 3) Testing how LSD works in the brain by modelling the effects in a whole-brain simulation
In the Research Briefing of October 11th 1) Good news for microdosing from a neuroimaging study 2) MDMA-assisted therapy could help those with with social anxiety disorder 3) Shamanistic practitioners show psychedelic-like brainwaves when drumming
In the Research Briefing of September 23rd 1) How ayahuasca ceremony leaders regard preparation and integration 2) Psychedelics for treating neurodegenerative disorders such as Alzheimer’s 3) The relative safety of LSD in research settings
In the Research Briefing of August 27th: 1) The considerable risks of ibogaine 2) Psychiatrists favourable about psychedelics as medicines 3) Quitting tobacco addiction after psychedelic use
In the Research Briefing of July 23rd: 1) LSD increases empathy via oxytocin independent of serotonin receptor activity 2) Low dose LSD engenders therapeutic processes by inducing suggestibility alongside psychosis-like phenomena and mystical experiences 3) Novel gene repression method improves the yield of psilocybin biosynthesis by over 300%